Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Proteomics

Cancer Proteomics Keynote Speakers



Ruedi Aebersold
Professor, Institute for Systems Biology

Prof. Ruedi Aebersold is one of the pioneers in the field of proteomics. He is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics like a new class of reagents termed Isotope Coded Affinity Tag (ICAT) reagents used in quantitative mass spectrometry. Prof. Dr. Aebersold and his team of researchers use the protein profiles determined by this method to differentiate cells in different states, such as noncancerous versus cancerous cells, and to systematically study how cells respond to external stimuli. These "snapshot" profiles indicate which cells contain abnormal levels of certain proteins. This is expected to lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes that control and constitute cell physiology.
Prof. Aebersold serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics.
Prof. Aebersold is a native of Switzerland and obtained his Ph.D. in Cellular Biology at the Biocenter of the University of Basel in 1983. Since that time, he is a faculty member of the Universities of Washington and British Columbia, until 2000, when he co-founded the Institute for Systems Biology in Seattle. In 2004, he accepted a position as full professor at the Institute of Biotechnology at the Swiss Federal Institute of Technology (ETH) in Zurich, where in January 2005, his research group became the first integral part of the newly founded Institute of Molecular Systems Biology.

Ruedi Aebersold Image
 

William Gallaghr
Chief Scientific Officer/Professor, OncoMark Limited/University College Dublin

Prof. Gallagher originally graduated from the Department of Biochemistry, UCD in 1993 with a 1st Class Joint Honours degree in Molecular Genetics and Biochemistry. Subsequently, he obtained a PhD in Molecular Oncology from the Cancer Research UK Beatson Laboratories in Glasgow. In 1997, he moved to Paris to undertake a Marie Curie Individual Fellowship at Rhone-Poulenc Rorer (currently Sanofi-Aventis). Afterwards, he returned to Ireland upon receipt of an Enterprise Ireland Post-Doctoral Fellowship (1999-2000) and, subsequently, a Marie Curie Return Fellowship (2000–2001). In 2001, he was employed in a permanent capacity as College Lecturer at UCD within the former Department of Pharmacology. In 2005, he was appointed Senior Lecturer within the UCD School of Biomolecular and Biomedical Science and promoted to Associate and Full Professor of Cancer Biology in 2006 and 2014, respectively. From September 2009-August 2011, Prof. Gallagher was the Vice-Principal of Research and Innovation at the UCD College of Life Sciences. He is also a Conway Fellow at the UCD Conway Institute. In 2007, he co-founded OncoMark Ltd., which is a private company centred on the development of diagnostics in the oncology arena (www.oncomark.com). Prof. Gallagher is currently the Chief Scientific Officer (CSO) at OncoMark. A major focus of Prof. Gallagher’s research work is the identification and validation of candidate biomarkers of breast cancer and melanoma, with particular emphasis on translation of transcriptomic and proteomic datasets into clinically relevant assays. In addition, his team (the Cancer Biology and Therapeutics Lab; www.cbtlab.ie) investigates the functional relevance of candidate tumour progression-associated genes at both in vitro and in vivo levels, as well as engages in preclinical evaluation of novel anti-cancer agents.


Prof. Gallagher is currently Director of BREAST-PREDICT, which is the first Irish Cancer Society Collaborative Cancer Research Centre (CCRC) to be funded (www.breastpredict.com). This country-wide CCRC, which is supported to the level of 7.5 million euro, runs from 2013 to 2018 and involves 6 academic institutions (UCD, TCD, RCSI, DCU, NUIG and UCC), as well as the not-for-profit clinical trials organisation, the All-Ireland Co-Operative Oncology Research Group (ICORG). Prof. Gallagher is also co-PI and Deputy Co-ordinator of a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer (2009-2014) (www.mtci.ie). He is also co-ordinator of a large-scale FP7 collaborative project, entitled RATHER (www.ratherproject.com), which is focused on providing new rationalised therapy options for difficult-to-treat breast cancer subtypes (2011-2015). This multi-million euro project involves 6 academic groups and 2 industrial parties across 5 EU countries. Prof. Gallagher also co-ordinates two Marie Curie Industry-Academia Partnerships and Pathways (IAPP) programmes under FP7, namely (1) FAST-PATH (www.fastpathproject.com) which is focused on applying high-performance computing and automated image analysis to fast-track pathological assessment in prostate cancer and (2) SYS-MEL (www.sysmel.com), which is focused on applying systems medicine approaches to development of new diagnostic solutions in melanoma.


Prof. Gallagher has received a number of awards based on his research work to date, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St. Luke’s Silver Medal Award in 2008 and the NovaUCD 2011 Innovation Award. Prof. Gallagher has had productive collaborative interactions with a variety of other industrial partners throughout his research, and has filed/been awarded multiple patents.

William Gallaghr Image
 

Samir Hanash
Director, University of Texas MD Anderson Cancer Center

Dr. Hanash is program head for Molecular Diagnostics at the Fred Hutchinson Cancer
Research Center in Seattle, Washington. Dr. Hanash’s interests and expertise focus on the
development and application of integrated approaches to the molecular profiling of cancer, with particular emphasis on proteomics. He has been a program principal investigator for several multi-investigator projects aimed at biomarker discovery and validation using
proteomics. Dr. Hanash has organized and participated in several workshops and initiatives related to diagnostics and proteomics. He is the inaugural president of the Human Proteome Organization.

Samir Hanash Image
 

Add to Calendar ▼2012-10-16 00:00:002012-10-17 00:00:00Europe/LondonCancer ProteomicsSELECTBIOenquiries@selectbiosciences.com